Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients-Reference-Cited by-同舟云学术

Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients

Published:2022-03 Issue: Volume:Volume 14 Page:863-873
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Xu Ziyi^ORCID,Hao Xuezhi,Wang Qi,Wang Jing,Yang Ke,Wang Shouzheng,Teng Fei,Li Junling,Xing Puyuan

Publisher

Informa UK Limited

Subject

Oncology

Reference39 articles.

1. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

2. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

3. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

4. EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

5. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reduced frequency dosing of osimertinib in EGFR-mutant non-small cell lung carcinoma: real world data;ecancermedicalscience;2024-06-28

2. Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and next-generation sequencing;Expert Review of Anticancer Therapy;2024-04-02

3. Reduced frequency dosing of osimertinib in EGFR-mutant non-small cell lung carcinoma: Real world data;2023-12-20

4. Efficacy of third-generation EGFR-TKIs in advanced NSCLC with different T790M statuses tested via ddPCR and NGS;2023-01-19

5. Targeting phospholipase C using synthetic inhibitors of EGFR signaling for cancer treatment;Phospholipases in Physiology and Pathology;2023